Elutia Inc Dossier - Source-backed chat

Elutia Inc

ELUTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.92

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.80Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $35.4M

Enterprise Value $41.6M

Shares Outstanding 44.8M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Elutia Inc. is undergoing a major strategic transformation, pivoting from a diversified biologics company to a highly focused pioneer in drug-eluting biomatrix (DEB) technologies. Following the successful $88 million divestiture of its BioEnvelope business to Boston Scientific in late 2025, Elutia has completely cleared its debt and built a robust cash runway to fund its next-generation NXT-41x platform. NXT-41x targets the $1.5 billion U.S. breast cancer surgery market, addressing post-operative infection rates of 15-20%. With the base biologic matrix NXT-41 on track for FDA clearance in late 2026 and the full drug-eluting NXT-41x expected in 1H 2027, Elutia represents a high-upside, well-capitalized biotech play with a validated platform and near-term regulatory catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$5.00

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

FDA issues additional information requests, delaying NXT-41 clearance into 2027 and NXT-41x into late 2027 or 2028. The strategic process for SimpliDerm fails to yield a transaction, forcing the company to continue funding its operations. Litigation with Medtronic results in unexpected liabilities, accelerating cash burn and requiring dilutive equity financing.

Base CaseCentral scenario

$5.0050%

Matches the consensus mean

FDA clears NXT-41 in Q4 2026 and NXT-41x in 1H 2027 as scheduled. The company maintains a disciplined cash burn rate, utilizing its $36.5 million in cash and escrowed funds. SimpliDerm strategic options are finalized, and initial surgeon engagement for NXT-41x confirms strong clinical demand, setting the stage for commercial launch in late 2027.

Bull CaseUpside scenario

$6.0030%

FDA clears NXT-41 ahead of schedule in Q3 2026, followed by rapid clearance of NXT-41x in early 1H 2027. The company successfully divests its SimpliDerm product line and Cardiovascular assets for non-dilutive cash, further strengthening its balance sheet. Commercial adoption of NXT-41x scales rapidly under CCO Pete Ligotti, capturing significant market share in the $1.5 billion breast reconstruction market and achieving gross margins exceeding 80% due to automated manufacturing.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $36.5 million in cash and escrowed proceeds as of Q1 2026, and zero outstanding debt following the repayment of the SWK Holdings facility.
Validated platform technology, as demonstrated by the $88 million sale of the EluPro and CanGaroo BioEnvelope business to Boston Scientific.
Large addressable market opportunity ($1.5 billion U.S. breast cancer surgery market) with a clear clinical unmet need to reduce post-operative infection rates.
High-margin potential, with automated manufacturing processes designed to support gross margins of over 80% at scale.

Key Investment Risks

Regulatory binary risk associated with the upcoming FDA 510(k) clearance of NXT-41 and the drug-eluting NXT-41x.
Commercial execution risk as the company transitions to launching a new product platform under newly appointed commercial leadership.
Ongoing litigation with Medtronic regarding breach of the 2019 Tissue Product Supply Agreement and related indemnity obligations.
Concentration of near-term revenue on legacy products (SimpliDerm and Cardiovascular) while the primary growth driver (NXT-41x) is still in development.

Thesis Invalidation Triggers

FDA rejection or significant delay of the NXT-41 510(k) application.
Failure to release the $8.0 million BioEnvelope divestiture escrow funds in Q4 2026.
An adverse court ruling in the Medtronic litigation resulting in material cash damages or ongoing indemnity liabilities.
Quarterly cash burn accelerating significantly beyond the current run rate without corresponding clinical or strategic milestones.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.